India to roll out COVID vaccines in weeks
>> Reuters
Published: 03 Jan 2021 12:53 PM BdST Updated: 03 Jan 2021 12:53 PM BdST
India's drugs regulator on Sunday gave final approval for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.
The world's second most populous country is now expected to start a massive immunisation programme within weeks, with the AstraZeneca/Oxford shot taking the lead and Bharat Biotech's COVAXIN administered under stricter conditions given no efficacy data has been release for it.
The overall efficacy of the AstraZeneca/Oxford vaccine was 70.42%, while Bharat Biotech's COVAXIN was "safe and provides a robust immune response", Drugs Controller General of India V.G. Somani said.
The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded COVISHIELD, while Bharat Biotech has teamed up with the government-run Indian Council of Medical Research.
"Vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situations," Somani read out from a written statement at a press conference. Somani did not take questions.
Both vaccines will be administered in two doses and stored at 2-8° degrees Celsius (36 to 48°F), he said. Sources told Reuters on Saturday the doses would have to be given four weeks apart.
Somani explained that the Bharat Biotech vaccine had been approved "in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains".
Prime Minister Narendra Modi welcomed the approvals.
"It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!" he said on Twitter, calling it a sign of a "self-reliant" country.
SII, the world's biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even without a formal supply deal with the government.
"All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off," CEO Adar Poonawalla said on Twitter. "COVISHIELD, India's first COVID-19 vaccine, is approved, safe, effective and ready to roll-out in the coming weeks."
-
Sri Lanka PM aims to cut expenditure
-
India to restrict sugar exports
-
Dozens dead or missing as Rohingya refugee boat sinks
-
Nepal raises retail fuel price
-
India heatwave puts millions at risk
-
Hindu women press for access to Indian mosque
-
Inflation crimps Indian firms
-
Navjot Singh Sidhu gets jail in 1988 road rage case
-
Sri Lanka's prime minister says will slash expenditure in new budget
-
India could restrict sugar exports to 10m tonnes
-
Rohingya refugee boat sinks off Myanmar, dozens dead or missing
-
Nepal raises retail fuel price, stoking inflation fears
-
Millions at risk as India's severe heatwave exposes cooling gaps
-
Bangladesh to assist Afghanistan with Tk 10m through UN
Most Read
- High Court denies 4 North South University trustees anticipatory bail, turns them over to police
- Square Pharmaceuticals factory fire doused after 7-hour fight in Gazipur
- Bangladesh names its longest bridge after Padma River as it opens on Jun 25
- Four trustees of North South University sent to jail, face grilling in embezzlement case
- Reserves rise slightly past $42bn as Bangladesh scrambles to calm a dwindling currency market
- Saudi Arabia suspends travel to India, 15 other nations as COVID cases surge
- Bangladesh raises duty on imports as it cracks down on luxuries
- Ban water taxis from ‘priceless’ Hatirjheel, High Court rules
- Students wings of BNP, Awami League clash at Dhaka University
- OC Pradip's wife Chumki surrenders to court in ACC case for having assets beyond means